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Treatment of Eczema Herpeticum
With Acyclovir
Robert N. J. Swart, MD; Bert Jan  Vermeer, MD; Jos W. M. van Der Meer, MD; 
Frederik A. J. Enschedé, MD; Jan Versteeg, MD
•  Eczema herpeticum is a serious herpes simplex virus infection that 
may have a fatal outcome. Effective antiviral therapy is therefore 
imperative. Acyclvoir (9-[2-hydroxyethoxymethyl]-guanine) is a new antiviral 
agent with high potency and low toxic effect. We treated three cases of 
eczema herpeticum successfully with acyclovir.
(Arch Dermatol 1983;119:13-16)
Eczema herpeticum, or Kaposi’s varicelliform  eruption due to herpesvirus hominis, is an 
uncommon disease usually found in individuals with  
atopic dermatitis. The disease is most frequently  
caused by a primary or recurrent infection with  
herpesvirus hominis type 1, but herpesvirus hominis 
type 2 may also be the responsible agent.'
The severity of eczema herpeticum ranges from  
mild and transient to fatal. Some of the fatalities are 
due to viremia with the resultant infection of inter­
nal organs such as the lungs, brain, liver, gastroin­
testinal tract, and adrenal glands.2 The exact mortal­
ity of the disease is unknown, but with the advent of 
modern antimicrobial treatment, it has been well 
below 10%2,3 although secondary bacterial infection  
may still contribute to a fatal outcome. Attem pts to 
treat eczema herpeticum with a variety of measures, 
especially antiviral agents, have been reported. The 
use of topical idoxuridine therapy, local applications
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of methylene blue in combination with light therapy, 
systemic cytarabine therapy, and vidarabine therapy 
have all been described.'0
In this article, we describe the use of acyclovir 
(9-[2-hydroxyethoxymethyl]-guanine), a new antivi­
ral agent with low toxic effect, in the treatment of 
three patients with eczema herpeticum.
REPORT OF CASES
C ase  1.—A 21-year-old man who had had atopic derm a­
titis since 2 years of age was hospitalized with acute 
dermatitis  and illness. Four days before admission, non­
itching vesicles had appeared on his cheeks. The following 
day, he had felt ill and had a tem perature  of 38.4 °C. Over 
the next few days, the vesicles appeared over his face, neck, 
shoulders, the upper par t  of the chest, and the upper arms. 
He had not been vaccinated recently against smallpox and 
had not been in contact with anyone who had recently 
received a smallpox vaccination. Neither the patient nor 
anyone in his family had a history of recurrent herpes 
simplex infection.
On admission, examination, disclosed an ill young man 
with a tem perature  of 38.8 °C. His face, particularly 
around the eyes, and his neck, shoulders, the upper pa r t  of 
the chest, and the upper arms, were diffusely covered with 
round, approximately 3-mm vesiculopustular lesions, all in 
the same stage of development (Fig 1). He also had 
periorbital edema and blepharitis. Corneal sensitivity was 
normal bilaterally, and there were no signs of keratitis, as
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Fig 2. — Appearance of patient 1 nine days after initiation of 
acyclovir therapy.
Fig 1.— Appearance of patient 1 before treatment
judged by fluorescence testing. Enlarged submandibular 
lymph nodes were palpable. Typical eczematous patches of 
atopic dermatitis  were present in the popliteal areas and 
over the ankles. The remainder of the physical findings 
were normal. Routine hematologic and serological studies 
gave normal results, except for a slight (subsequently 
transient) elevation of the transam inase  values.
Bacteriologic cultures of material from the nose and skin 
lesions yielded Staphylococcus aureus and Streptococcus 
hemolyticus group B; both organisms were sensitive to 
erythromycin. A Tzanck smear of the contents of a vesicle 
showed multinucleated giant cells. A biopsy specimen from 
an active skin lesion showed a circumscribed area of 
epidermal cell degeneration with nuclear inclusion bodies, 
the formation of multinucleated giant cells, acantholysis, 
and necrosis with ulceration. These histological alterations 
were considered to be characteristic of a herpes simplex 
vesicle. Microscopic examination of the adjacent skin 
showed a mild chronic derm atitis  compatible with the 
changes of chronic atopic dermatitis.
Because of a presumed bacterial component to the 
infection, the patient began t rea tm en t  with erythromycin, 
1 g /day  orally, a t  the time of admission. Once the diagnosis 
of eczema herpeticum was confirmed by the findings on 
the Tzanck test and virological cultures, acyclovir was 
given intravenously (IV), s ta r t ing  on the third hospital 
day, in a dosage of 500 mg three times a day (20 mg/kg) for 
five days. Within 24 hours after  initiation of treatm ent,  
the pa tien t’s tem perature  became normal and he felt
better. No new lesions appeared after this t rea tm en t  was 
started. Local t rea tm en t  consisted of 5% sulfur cream and 
wet gauze pads applied to his edematous eyelids four times 
a day. Nine days after institution of acyclovir therapy, all 
vesicles and crusts had healed (Fig 2).
The virological findings in this case are illustrated in Fig
3. Samples for virus isolation taken from the base of a 
lesion at the time of admission and on the fourth day of 
t rea tm en t were positive for herpesvirus in tissue culture. 
Culture of a specimen taken on the sixth hospital day 
showed no growth. Antibody titers, determined by the 
immune-adherence hemagglutination test to herpesvirus 
hominis type 1, rose from 64 on the first day to 512 after  
two weeks. IgM antibodies against herpes simplex virus 
were not detectable.
C ase 2 .— One week before admission, an 11-year-old girl, 
who had had atopic derm atitis  and as thm a since infancy, 
had played with a child with a herpes infection on her lips. 
Two days later, a vesicle developed on the pa tien t’s lower 
lip. Three days thereafter, multiple vesicles appeared over 
her body and her tem perature  rose to 40 °C. On admission 
to the hospital, examination disclosed th a t  the entire skin 
surface was covered with vesiculopapular lesions tha t  
contained a clear fluid; all were in the same stage of 
development. The popliteal areas, ankles, wrists, and 
elbows showed typical lesions of atopic dermatitis. The 
physical findings were otherwise normal. A Tzanck smear 
of a vesicle showed multinucleated giant cells. Bacteriolog­
ic culture of material from the skin lesions yielded S
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Fig 3.— Clinical course and virological findings in patient 1.
aureus. On the second hospital day, t rea tm en t  was begun 
with acyclovir, ‘250 mg IV three times a day (20 mg/kg) for 
five days. No antibacterial therapy was administered. 
Within 24 hours after t rea tm en t  was instituted, her body 
tem perature  dropped to normal; five days later, all lesions 
had healed. Samples for virus isolation taken on the first 
and third day of t rea tm en t  were positive for herpesvirus; a 
sample taken on the sixth day yielded no growth. Antibody 
titers, determined by the immune-adherence hemaggluti­
nation test to herpesvirus hominis type 1, rose from 8 to 
128 after two weeks. IgM antibodies against herpes sim­
plex virus showed a t i ter  of 62.
C ase  3 .—A 10-year-old boy, known to suffer from atopic 
dermatitis, was admitted to the hospital acutely ill, with a 
vesicular rash on his face and a tem perature  of 40.1 °C. 
Three days before admission, he had had a tem perature  of 
39.0 °C; a rash had appeared on the same day. On exami­
nation, his face was covered with clear vesicles, all in the 
same stage of development. There was severe periorbital 
edema. The other physical findings were normal. He was 
treated with acyclovir, 250 mg IV three times a day (20 
mg/kg) for five days. No antibiotic therapy was given. The 
tem perature  dropped to normal within 24 hours; after six 
days, all of the skin lesions had healed. On the second day 
of treatm ent,  he had a trans ien t  hallucinatory state; no 
neurological abnormalities were found. A spinal tap was 
done. The CSF demonstrated no abnormalities, and im mu­
nofluorescence of the CSF showed no evidence of CNS 
herpes infection.'’ Skin samples for virus isolation, taken on 
the first and th ird  days of trea tm ent,  were positive for 
herpesvirus, but thereafter  were negative. Antibody ti ters  
to herpesvirus hominis type 1 rose from 0 to 32 after two 
weeks. IgM antibodies against herpes simplex virus 
showed a t i te r  of 62.
COMMENT
Because of a certain, albeit low, mortality, eczema 
herpeticum may be a serious disease. Effective treat­
ment of the patient is directed toward the prevention 
of viremia and involvement of internal organs, and
the control of secondary bacterial infection. At 
present, there are four antiviral agents to be consid­
ered for use in patients with serious herpesvirus 
infections: idoxuridine, vidarabine, interferon, and 
acyclovir.7-8 The experience with new drugs, such as 
bromovinyl desoxyuridine and phosphonoformic acid 
(foscarnet sodium is the international nonproprie­
tary name for the trisodium salt), is still too limited  
to consider them for clinical use. Systemic idoxurid­
ine toxic effect permits only topical applications of 
the drug, and it seems doubtful that a local agent 
could prevent viremia as effectively as one given 
systemically.
Systemic cytarabine has been claimed to be effec­
tive in the treatm ent of eczema herpeticum,5 but it 
can no longer be recommended for antiviral treat­
ment because it has proved to be more toxic than  
vidarabine. Even so, vidarabine has a number of 
serious side effects, including nausea, vomiting, diar­
rhea, tremors, thrombocytopenia, and leukocytope- 
nia; neurological abnormalities have also been 
observed.8 Recently, the treatment of eczema herpet­
icum with vidarabine has been reported.910 Unfortu­
nately, both patients died of bacterial septicemia.
Interferon given in high doses might have benefi­
cial effects in the treatment of eczema herpeticum, 
but we found no reports of its successful use for this 
infection. Interferons are difficult to obtain and 
expensive. The selection of an appropriate interferon 
and its effective dosage pose difficult problems.8
Acyclovir (9-[2-hydroxyethoxymethyl]-guanine) is 
a new antiviral agent with low toxicity for normal 
cells and greater inhibitory activity against herpes­
virus hominis than any compound previously stud­
ied.“•'2 In vitro, acyclovir is converted to a 
monophosphate by a virus-specific thymidine kinase; 
subsequently, it is converted into diphosphate and
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triphosphate forms.13 In the triphosphate form, acy­
clovir acts by inhibiting viral DNA polymerase 30 
times more strongly than it inhibits normal cellular 
DNA polymerase. The inhibition of viral DNA poly­
merase selectively stops replication of the infecting  
herpesvirus. In studies done in mice, rabbits, and 
guinea pigs, acyclovir has been shown to be effective 
in the treatment of encephalitis, keratitis, and skin 
lesions caused by a herpesvirus.l2-14'16 In man, the 
treatment results in viral pneumonia, mucocutane­
ous herpes simplex infection, and herpes zoster 
infection with acyclovir have been reported.l7',,) The 
first and impressive results of controlled trials of the 
drug in herpes simplex and herpes zoster infections 
have recently been published.20" These well-con­
trolled clinical trials demonstrated strong antiviral 
effects of acyclovir, in contrast to the largely anec­
dotal efficacy of the aforementioned antiviral drugs 
claimed for the treatment of eczema herpeticum.
For the three patients described in this article, the 
institution of acyclovir therapy had a dramatic effect 
on body temperature and the cutaneous lesions. In 
each case, the rapid cessation in the spread of the 
eruption and the overall clinical improvement in the 
patient’s condition during the first days of treatment 
were impressive. As the secondary bacterial infec­
tion played a minor role in cases 2 and 3, no 
antibiotics were given. Nevertheless, the body tem ­
perature and skin condition improved very rapidly 
during the treatment course with acyclovir in both of 
these patients. In cases 2 and 3, IgM antibodies 
against herpes simplex virus were detectable, indi­
cating a primary infection with the herpes simplex  
virus.
Compared with other antiviral drugs, acyclovir 
seems to be remarkably free of side effects to date. 
Transient impairment of renal function, transient 
rises in transaminase levels, and delirium have been 
reported.,S21-23 In our patients, the slight elevation of 
transaminase values in patient 1 and the hallucina­
tory state in patient 3 should probably be ascribed to 
acyclovir, although the possibility that these effects 
were produced by the virus itself cannot be complete­
ly ruled out. Nonetheless, the potential toxic effect of 
the drug cannot be fully evaluated as yet because of 
its still limited use.
Acyclovir seems to be an effective antiviral agent 
that deserves a place in the treatment of serious 
herpesvirus infections.
Erik Scheffer, MD, in terpre ted  the histological findings. W er­
ner A. H errm ann ,  MD, trea ted  pa t ien t  3.
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